"CA-125 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A carbohydrate antigen that occurs in tumors of the ovary as well as in breast, kidney, and gastrointestinal tract tumors and normal tissue. While it is tumor-associated, it is not tumor-specific and may have a protective function against particles and infectious agents at mucosal surfaces.
| Descriptor ID |
D018394
|
| MeSH Number(s) |
D12.776.395.560.631.050 D23.050.285.050.225 D23.050.550.325.225 D23.101.140.075.225
|
| Concept/Terms |
CA-125 Antigen- CA-125 Antigen
- Antigen, CA-125
- Antigen CA-125
- Antigen CA 125
- Mucin-16
- Mucin 16
- CA 125 Antigen
- Antigen, CA 125
|
Below are MeSH descriptors whose meaning is more general than "CA-125 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Mucoproteins [D12.776.395.560]
- Mucins [D12.776.395.560.631]
- CA-125 Antigen [D12.776.395.560.631.050]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Neoplasm [D23.050.285]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.285.050]
- CA-125 Antigen [D23.050.285.050.225]
- Epitopes [D23.050.550]
- Antigens, Tumor-Associated, Carbohydrate [D23.050.550.325]
- CA-125 Antigen [D23.050.550.325.225]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Antigens, Tumor-Associated, Carbohydrate [D23.101.140.075]
- CA-125 Antigen [D23.101.140.075.225]
Below are MeSH descriptors whose meaning is more specific than "CA-125 Antigen".
This graph shows the total number of publications written about "CA-125 Antigen" by people in this website by year, and whether "CA-125 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "CA-125 Antigen" by people in Profiles.
-
Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites. Immunol Invest. 2021 Jul; 50(5):562-579.
-
Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. Am J Respir Crit Care Med. 2020 01 15; 201(2):250-253.
-
Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules. Am J Obstet Gynecol. 2017 12; 217(6):652-660.
-
Applicability of the modified ACOG/SGO referral criteria for adnexal mass within a limited-resource setting. Int J Gynaecol Obstet. 2017 Jan; 136(1):53-57.
-
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
-
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One. 2011; 6(12):e29180.
-
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
-
Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72.
-
Biomarkers for the early detection of cancer: an inflammatory concept. Arch Intern Med. 2007 Sep 24; 167(17):1822-4.
-
Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics. 2005 Nov; 5(17):4625-36.